• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Cxbladder tests identify high-impact and low-impact tumors


“The purpose of [Cxbladder] Resolve is to identify not only those patients who are at higher risk for urothelial or urinary tract cancer, but those that have a high probability of an aggressive cancer, such as high-grade TA, carcinoma in situ, or T1 to T3,” says Jay Raman, MD, FACS.

In this video, Jay Raman, MD, FACS, discusses how the urinary biomarker Cxbladder tests are used to classify the risk of urothelial cancer in patients with hematuria. Raman is a professor and chair of urology at Penn State Health Milton S. Hershey Medical Center, Penn State University, Pennsylvania.

Related Videos
doctor showing a patient some information on a digital tablet | Image Credit: © bongkarn - stock.adobe.com
Blurred interior of hospital | Image Credit: © jakkapan - stock.adobe.com
A panel of 5 experts on bladder cancer
A panel of 5 experts on bladder cancer
Diverse doctors having a conversation |  Image Credit: © Flamingo Images - stock.adobe.com
David I. Lee, MD, FACS, answers a question during a video interview
Related Content
© 2024 MJH Life Sciences

All rights reserved.